Validation and comparison of anti-αvβ3 and anti-αvβ5 rabbit monoclonal versus murine monoclonal antibodies in four different tumor entities

Applied Immunohistochemistry and Molecular Morphology

Volumn 21, Issue 6, 2013, Pages 553-560

  Böger, Christine ^a   Kalthoff, Holger ^a   Goodman, Simon L ^b   Röcken, Christoph ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b MERCK KGAA   (Germany)

Author keywords

v 3; v 5; FFPE tissue; Immunohistochemistry; Integrins; Rabmabs; Validation

Indexed keywords

ALPHAVBETA3 INTEGRIN ANTIBODY; ALPHAVBETA5 INTEGRIN; ALPHAVBETA5 INTEGRIN ANTIBODY; FORMALDEHYDE; MONOCLONAL ANTIBODY; PARAFFIN; RABBIT ANTISERUM; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER TISSUE; COLORECTAL CARCINOMA; CONTROLLED STUDY; CRYOPRESERVATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNODETECTION; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; RABBIT MODEL; TISSUE SECTION; VALIDATION PROCESS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CARCINOMA; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; INTEGRIN ALPHAVBETA3; LUNG NEOPLASMS; MALE; MICE; MIDDLE AGED; NEOPLASMS; OVARIAN NEOPLASMS; PARAFFIN EMBEDDING; RABBITS; RECEPTORS, VITRONECTIN; SPECIES SPECIFICITY; TISSUE FIXATION;

EID: 84892443074     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e318284a03a     Document Type: Article

References (31)

1. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10:9-22.
2. Desgrosellier JS, Barnes LA, Shields DJ, et al. An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat Med. 2009;15:1163-1169.
3. Hehlgans S, Haase M, Cordes N. Signalling via integrins: implications for cell survival and anticancer strategies. Biochem Biophys Acta. 2007;1775:163-180.
4. Schwartz MA, Ginsberg MH. Networks and crosstalk: integrin signalling spreads. Nat Cell Biol. 2002;4:E65-E68.
5. Cheresh DA, Smith JW, Cooper HM, et al. A novel vitronectin receptor integrin (alpha v beta x) is responsible for distinct adhesive properties of carcinoma cells. Cell. 1989;57:59-69.
6. Smith JW, Cheresh DA. Integrin (alpha v beta 3)-ligand interaction. Identification of a heterodimeric RGD binding site on the vitronectin receptor. J Biol Chem. 1990;265:2168-2172.
7. Wayner EA, Orlando RA, Cheresh DA. Integrins alpha v beta 3 and alpha v beta 5 contribute to cell attachment to vitronectin but differentially distribute on the cell surface. J Cell Biol. 1991;113:919-929.
8. Vonlaufen A, Wiedle G, Borisch B, et al. Integrin alpha(v)beta(3) expression in colon carcinoma correlates with survival. Mod Pathol. 2001;14:1126-1132.
9. Maubant S, Cruet-Hennequart S, Dutoit S, et al. Expression of alpha V- A ssociated integrin beta subunits in epithelial ovarian cancer andits relation to prognosis in patients treated with platinumbased regimens. J Mol Histol. 2005;36:119-129.
10. Berry MG, Gui GPH, Wells CA, et al. Integrin expression and survival in human breast cancer. Eur J Surg Oncol. 2004;30:484-489.
11. Max R, Gerritsen RR, Nooijen PT, et al. Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor- A ssociated vessels of human carcinomas. Int J Cancer. 1997;71:320-324.
12. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157-1164.
13. Kumar CC, MalkowskiM, Yin Z, et al. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist. Cancer Res. 2001;61:2232-2238.
14. Mitjans F, Meyer T, Fittschen C, et al. In vivo therapy of malignant melanoma by means of antagonists of alphav integrins. Int J Cancer. 2000;87:716-723.
15. Cox D, Brennan M, Moran N. Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov. 2010;9:804-820.
16. Goodman SL, Picard M. Integrins as therapeutic targets. Trends Pharmacol Sci. 2012;33:405-412.
17. Tabatabai G, Weller M, Nabors B, et al. Targeting integrins in malignant glioma. Target Oncol. 2010;5:175-181.
18. Goodman SL, Grote HJ, Wilm C. Matched rabbit monoclonal antibodies against av-series integrins reveal a novel avb3-LIBS epitope, and permit routine staining of archival paraffin samples of human tumors. Biol Open. 2012;1:329-340.
19. Sachs L, Hedderich J. Angewandte Statistik. Methodensammlung mit R. 12 ed. Heidelberg: Springer Verlag; 2010.
20. Reardon DA, Neyns B, Weller M, et al. Cilengitide: An RGD pentapeptide alphavbeta3 and alphavbeta5 integrin inhibitor in development for glioblastoma and other malignancies. Future Oncol. 2011;7:339-354.
21. Felding-Habermann B, O'Toole TE, Smith JW, et al. Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci USA. 2001;98:1853-1858.
22. Liu H, Radisky DC, Yang D, et al. MYC suppresses cancer metastasis by direct transcriptional silencing of [alpha]v and [beta]3 integrin subunits. Nat Cell Biol. 2012;14:567-574.
23. Albert JM, Cao C, Geng L, et al. Integrin alpha v beta 3 antagonist cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models. Int J Radiat Oncol Biol Phys. 2006;65:1536-1543.
24. Byzova TV, Rabbani R, D'Souza SE, et al. Role of integrin alpha(v)beta3 in vascular biology. Thromb Haemost. 1998;80: 726-734.
25. Shattil SJ. Function and regulation of the beta 3 integrins in hemostasis and vascular biology. Thromb Haemost. 1995;74: 149-155.
26. Hynes RO. Integrins: A family of cell surface receptors. Cell. 1987;48:549-554.
27. Kawahara E, Ooi A, Nakanishi I. Integrin distribution in gastric carcinoma: Association of beta 3 and beta 5 integrins with tumor invasiveness. Pathol Int. 1995;45:493-500.
28. Cheresh DA, Spiro RC. Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor. J Biol Chem. 1987;262:17703-17711.
29. Weinacker A, Chen A, Agrez M, et al. Role of the integrin alpha v beta 6 in cell attachment to fibronectin-heterologous expression of intact and secreted forms of the receptor. J Biol Chem. 1994;269: 6940-6948.
30. Powell WC, Hicks DG, Prescott N, et al. A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility. Appl Immunohistochem Mol Morphol. 2007;15: 94-102.
31. Bakeman R, Quera V, McArthur D, et al. Detecting sequential patterns and determining their reliability with fallible observers. Psychol Methods. 1997;2:357-370.